Anti‐BCMA Immuno‐NanoPET Radiotracers for Improved Detection of Multiple Myeloma
Current clinical imaging modalities for the sensitive and specific detection of multiple myeloma (MM) rely on nonspecific imaging contrast agents based on gadolinium chelates for magnetic resonance imaging (MRI) or for 18 F-FDG-directed and combined positron emission tomography (PET) and computed to...
| Main Authors: | , , , , , , , , |
|---|---|
| Other Authors: | |
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022
|
| Online Access: | https://hdl.handle.net/1721.1/141216 |
| _version_ | 1811084481372618752 |
|---|---|
| author | Thomas, Eloise Mathieu, Clélia Moreno‐Gaona, Patricia Mittelheisser, Vincent Lux, François Tillement, Olivier Pivot, Xavier Ghoroghchian, Paiman Peter Detappe, Alexandre |
| author2 | Koch Institute for Integrative Cancer Research at MIT |
| author_facet | Koch Institute for Integrative Cancer Research at MIT Thomas, Eloise Mathieu, Clélia Moreno‐Gaona, Patricia Mittelheisser, Vincent Lux, François Tillement, Olivier Pivot, Xavier Ghoroghchian, Paiman Peter Detappe, Alexandre |
| author_sort | Thomas, Eloise |
| collection | MIT |
| description | Current clinical imaging modalities for the sensitive and specific detection of multiple myeloma (MM) rely on nonspecific imaging contrast agents based on gadolinium chelates for magnetic resonance imaging (MRI) or for 18 F-FDG-directed and combined positron emission tomography (PET) and computed tomography (CT) scans. These tracers are not, however, able to detect minute plasma cell populations in the tumor niche, leading to false negative results. Here, a novel PET-based anti-BCMA nanoplatform labeled with 64 Cu is developed to improve the monitoring of these cells in both the spine and femur and to compare its sensitivity and specificity to more conventional immunoPET (64 Cu labeled anti-BCMA antibody) and passively targeted PET radiotracers (64 CuCl2 and 18 F-FDG). This proof-of-concept preclinical study confirmed that by conjugating up to four times more radioisotopes per antibody with the immuno-nanoPET platform, an improvement in the sensitivity and in the specificity of PET to detect tumor cells in an orthotopic model of MM is observed when compared to the traditional immunoPET approach. It is anticipated that when combined with tumor biopsy, this immuno-nanoPET platform may improve the management of patients with MM. |
| first_indexed | 2024-09-23T12:51:28Z |
| format | Article |
| id | mit-1721.1/141216 |
| institution | Massachusetts Institute of Technology |
| language | English |
| last_indexed | 2024-09-23T12:51:28Z |
| publishDate | 2022 |
| publisher | Wiley |
| record_format | dspace |
| spelling | mit-1721.1/1412162023-02-03T19:33:32Z Anti‐BCMA Immuno‐NanoPET Radiotracers for Improved Detection of Multiple Myeloma Thomas, Eloise Mathieu, Clélia Moreno‐Gaona, Patricia Mittelheisser, Vincent Lux, François Tillement, Olivier Pivot, Xavier Ghoroghchian, Paiman Peter Detappe, Alexandre Koch Institute for Integrative Cancer Research at MIT Current clinical imaging modalities for the sensitive and specific detection of multiple myeloma (MM) rely on nonspecific imaging contrast agents based on gadolinium chelates for magnetic resonance imaging (MRI) or for 18 F-FDG-directed and combined positron emission tomography (PET) and computed tomography (CT) scans. These tracers are not, however, able to detect minute plasma cell populations in the tumor niche, leading to false negative results. Here, a novel PET-based anti-BCMA nanoplatform labeled with 64 Cu is developed to improve the monitoring of these cells in both the spine and femur and to compare its sensitivity and specificity to more conventional immunoPET (64 Cu labeled anti-BCMA antibody) and passively targeted PET radiotracers (64 CuCl2 and 18 F-FDG). This proof-of-concept preclinical study confirmed that by conjugating up to four times more radioisotopes per antibody with the immuno-nanoPET platform, an improvement in the sensitivity and in the specificity of PET to detect tumor cells in an orthotopic model of MM is observed when compared to the traditional immunoPET approach. It is anticipated that when combined with tumor biopsy, this immuno-nanoPET platform may improve the management of patients with MM. 2022-03-16T15:41:49Z 2022-03-16T15:41:49Z 2022-01 2022-03-16T15:34:24Z Article http://purl.org/eprint/type/JournalArticle https://hdl.handle.net/1721.1/141216 Thomas, Eloise, Mathieu, Clélia, Moreno‐Gaona, Patricia, Mittelheisser, Vincent, Lux, François et al. 2022. "Anti‐BCMA Immuno‐NanoPET Radiotracers for Improved Detection of Multiple Myeloma." Advanced Healthcare Materials, 11 (2). en 10.1002/adhm.202101565 Advanced Healthcare Materials Creative Commons Attribution 4.0 International license https://creativecommons.org/licenses/by/4.0/ application/pdf Wiley Wiley |
| spellingShingle | Thomas, Eloise Mathieu, Clélia Moreno‐Gaona, Patricia Mittelheisser, Vincent Lux, François Tillement, Olivier Pivot, Xavier Ghoroghchian, Paiman Peter Detappe, Alexandre Anti‐BCMA Immuno‐NanoPET Radiotracers for Improved Detection of Multiple Myeloma |
| title | Anti‐BCMA Immuno‐NanoPET Radiotracers for Improved Detection of Multiple Myeloma |
| title_full | Anti‐BCMA Immuno‐NanoPET Radiotracers for Improved Detection of Multiple Myeloma |
| title_fullStr | Anti‐BCMA Immuno‐NanoPET Radiotracers for Improved Detection of Multiple Myeloma |
| title_full_unstemmed | Anti‐BCMA Immuno‐NanoPET Radiotracers for Improved Detection of Multiple Myeloma |
| title_short | Anti‐BCMA Immuno‐NanoPET Radiotracers for Improved Detection of Multiple Myeloma |
| title_sort | anti bcma immuno nanopet radiotracers for improved detection of multiple myeloma |
| url | https://hdl.handle.net/1721.1/141216 |
| work_keys_str_mv | AT thomaseloise antibcmaimmunonanopetradiotracersforimproveddetectionofmultiplemyeloma AT mathieuclelia antibcmaimmunonanopetradiotracersforimproveddetectionofmultiplemyeloma AT morenogaonapatricia antibcmaimmunonanopetradiotracersforimproveddetectionofmultiplemyeloma AT mittelheisservincent antibcmaimmunonanopetradiotracersforimproveddetectionofmultiplemyeloma AT luxfrancois antibcmaimmunonanopetradiotracersforimproveddetectionofmultiplemyeloma AT tillementolivier antibcmaimmunonanopetradiotracersforimproveddetectionofmultiplemyeloma AT pivotxavier antibcmaimmunonanopetradiotracersforimproveddetectionofmultiplemyeloma AT ghoroghchianpaimanpeter antibcmaimmunonanopetradiotracersforimproveddetectionofmultiplemyeloma AT detappealexandre antibcmaimmunonanopetradiotracersforimproveddetectionofmultiplemyeloma |